Latest:
Primary Overall Survival Analysis of the Phase 3 Randomized ZUMA‑7 Study of Axicabtagene Ciloleucel Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest:
Primary Overall Survival Analysis of the Phase 3 Randomized ZUMA‑7 Study of Axicabtagene Ciloleucel Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma
Latest:
Positioning ADCs and CAR T in R/R Multiple Myeloma
Latest:
FDA Involvement in Dose Optimization Through Project Optimus Drives a Patient-Focused Oncology Pharmacology Career: With D. Ross Camidge, MD, PhD; and Jeanne Fourie Zirkelbach, PhD
Latest:
JAK Inhibitors Continue to Shape the Treatment Landscape of Myelofibrosis
Latest:
Dr Hoppe on Outcomes of the CheckMate 744 Trial in Hodgkin Lymphoma
Latest:
Dr Winter on the Role of Treatment History in Richter Transformation